---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-146313"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-05-17T23:59:59+00:00"
generated_at: "2026-06-14T22:35:42.301875+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics annual meeting elects three Class II directors, ratifies KPMG

## Summary
- Elected Maha Katabi, Ph.D., Michael M. Morrissey, Ph.D., and Patrick G. Enright as Class II directors to serve until 2026.
- Katabi received 27,427,581 votes for, 1,803,342 withheld; Morrissey 25,666,331 for, 3,564,592 withheld; Enright 29,205,775 for, 25,148 withheld.
- Stockholders ratified KPMG LLP as independent auditor for FY2023 with 35,575,486 votes for, 3,251 against, 12,777 abstentions.
- 44,261,109 shares of Class A common stock were outstanding and entitled to vote as of March 17, 2023 record date.

## SEC filing metadata
- accession: 0001193125-23-146313
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-05-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312523146313/0001193125-23-146313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312523146313/d443819d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-146313
- JSON: https://secwatch.observer/filing/0001193125-23-146313.json
- Plain text: https://secwatch.observer/filing/0001193125-23-146313.txt

## Key facts
- Shareholder Votes
  Vera Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm at the 2023-05-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-10
  source text: The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 35,575,486 3,251 12,777 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312523146313/0001193125-23-146313-index.htm
- Shareholder Votes
  Vera Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2023-05-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-10
  source text: The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Maha Katabi, Ph.D. 27,427,581 1,803,342 6,360,591 Michael M Morrissey, Ph.D. 25,666,331 3,564,592 6,360,591 Patrick G. Enright 29,205,775 25,148 6,360,591
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312523146313/0001193125-23-146313-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.